Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abivax, Actinogen, ADC, Affimed, Akebia, Aldeyra, Alnylam, Alvotech, Aquestive, Astrazeneca, Benevolentai, Edesa, Genentech, Genmab, Gilead, Gradalis, Iaso, Innocare, Merck, Mirati, Onkyo, Outlook, Pfizer, Radius, Regenxbio, Sanofi, Sobi.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aerami, Akero, Armata, Astrazeneca, Bavarian Nordic, Beckley, Biontech, Bridgebio, Chemomab, Contrafect, Exelixis, Imago, Imbrium, Kempharm, Lexicon, Melt, Minovia, Mirata, Osivax, RQ, Sirnaomics, Small, Sosei, Vir, Viridian, Zynerba.

Emory University has identified deuterated and/or methylated N4-hydroxycytidine (NHC) analogues reported to be useful for the treatment of viral infections.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Altimmune, Arcus, Athenex, Biolinerx, Erasca, Journey Medical, Magenta, Nanology, Nykode, Oncotherapeutics, Quantum Leap, Regimmune, Satsuma, Simcere, Takeda, Ultimovacs, Verona.

U.S. federal authorities have made a lot of noise over inappropriate medical testing in the past two years, largely due to the COVID-19 pandemic, but Paul Garcia, a partner in the San Diego office of Hooper, Lundy & Bookman PC, says this trend will not ebb at all in the coming year. Garcia told BioWorld that the lookback period for Medicare testing claims runs several years and that not only will enforcement results continue to surface next year, but also that the associated civil monetary penalties could force a testing lab to shutter its operations permanently.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Amgen, Angiocrine, Arrowhead, Carrick, Catalyst, Eisai, Menarini, Merck, Paratek, Pfizer, Royalty.